摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(methanesulfonyl)-7-oxa-3-azabicyclo[4.1.0]heptane | 84794-11-6

中文名称
——
中文别名
——
英文名称
3-(methanesulfonyl)-7-oxa-3-azabicyclo[4.1.0]heptane
英文别名
3,4-epoxy-1-methanesulfonylpiperidine;3-(Methylsulfonyl)-7-oxa-3-azabicyclo[4.1.0]heptane;3-methylsulfonyl-7-oxa-3-azabicyclo[4.1.0]heptane
3-(methanesulfonyl)-7-oxa-3-azabicyclo[4.1.0]heptane化学式
CAS
84794-11-6
化学式
C6H11NO3S
mdl
——
分子量
177.224
InChiKey
LEKAQIKGOSYEKU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    78-79 °C(Solv: ethanol (64-17-5))
  • 沸点:
    302.1±44.0 °C(Predicted)
  • 密度:
    1.42±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.6
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    58.3
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • 4-aminopyrimidine-5-one derivatives
    申请人:——
    公开号:US20040162303A1
    公开(公告)日:2004-08-19
    Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.
    本发明揭示了新型4-氨基嘧啶-5-酮衍生物。这些化合物抑制细胞周期蛋白依赖性激酶,特别是细胞周期蛋白依赖性激酶4(Cdk4)。这些化合物及其药学上可接受的盐和酯具有抗增殖活性,并可用于治疗或控制癌症,特别是实体瘤。本发明还涉及含有这些化合物的制药组合物以及治疗或控制癌症的方法,尤其是乳腺、肺、结肠和前列腺肿瘤的治疗或控制。此外,还揭示了制备这些新型4-氨基嘧啶-5-酮衍生物的中间体。
  • 4-Aminopyrimidine-5-one derivatives
    申请人:Hoffmann-La Roche Inc.
    公开号:US07157455B2
    公开(公告)日:2007-01-02
    Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.
    本发明披露了新型4-氨基嘧啶-5-酮衍生物。这些化合物抑制细胞周期依赖性激酶,特别是细胞周期依赖性激酶4(Cdk4)。这些化合物及其药学上可接受的盐和酯具有抗增殖活性,并且在治疗或控制癌症,特别是实体瘤方面非常有用。本发明还涉及含有这些化合物的制药组合物以及治疗或控制癌症的方法,特别是乳腺癌、肺癌、结肠癌和前列腺癌的治疗或控制方法。还披露了在制备这些新型4-氨基嘧啶-5-酮衍生物过程中有用的中间体。
  • Cyclin dependent kinase inhibitors
    申请人:Pfizer Inc.
    公开号:US10766884B2
    公开(公告)日:2020-09-08
    This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    本发明涉及式(I)化合物 或其药学上可接受的盐,其中 R 基团 R1 至 R23、A、Q、U、V、W、X、Y、Z、n、p 和 q 如本文所定义;包含此类化合物和盐的药物组合物;以及使用此类化合物、盐和组合物治疗受试者异常细胞生长(包括癌症)的方法。
  • IMANISHI, TAKESHI;SHIN, HIROAKI;HANAOKA, MIYOJI;MOMOSE, TAKEFUMI;IMANISHI+, CHEM. AND PHARM. BULL., 1982, 30, N 10, 3617-3623
    作者:IMANISHI, TAKESHI、SHIN, HIROAKI、HANAOKA, MIYOJI、MOMOSE, TAKEFUMI、IMANISHI+
    DOI:——
    日期:——
  • 4-AMINOPYRIMIDINE-5-ONE
    申请人:F.HOFFMANN-LA ROCHE AG
    公开号:EP1628619A2
    公开(公告)日:2006-03-01
查看更多

同类化合物

7-亚乙基-环戊二烯并(b)环氧乙烷并(c)吡啶六氢衍生物. 4-甲基-3-氧杂-6-氮杂三环[3.2.0.02,4]庚烷-7-酮 3-氧杂-6-氮杂三环[3.2.2.02,4]壬烷(8CI,9CI) 3-氧杂-1-氮杂三环[5.2.0.02,4]壬烷 2-氧杂-6-氮杂三环[4.3.1.01,3]癸烷 (1S,2R,4S,5R)-3-氧杂-6-氮杂三环[3.2.1.02,4]辛烷-7-酮 (5R,7S,8R,8aR)-5-dodecyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one (2S,2R,4S,5R,6S)-(+)-2-{2-[2-[1,3]-dioxolan-2-yl-ethyl]-6-methyl-4,5-epoxy-3,6-dihydro-2H-pyridin-1-yl}-2-phenylethanol (5R,7R,8S,8aR)-5-ethyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one dihydroabikoviromycin (1R,6R)-1-(hydroxymethyl)-3-[(1S)-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1S,6S)-1-(hydroxymethyl)-3-[(1S)-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1aR,6aS,7R,7aS)-7-(t-butyldimethylsilyloxy)tetrahydro-1aH-oxazolo[3,4-a]oxireno[2,3-d]pyridin-4(2H)-one 11-formyl-(1rN,2tH,4tH,6cN,7tH,9tH)-3,8-dioxa-11-aza-tetracyclo[4.4.1.02,4.07,9]undecane 7-Oxa-2-azabicyclo[4.1.0]heptane (1S,6S)-1-(hydroxymethyl)-3-[(1R)-2-hydroxy-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6R)-1-(hydroxymethyl)-3-[(1R)-2-hydroxy-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6R)-3-[(1R)-2-[tert-butyl(dimethyl)silyl]oxy-1-phenylethyl]-1-(hydroxymethyl)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1S,6S)-3-[(1R)-2-[tert-butyl(dimethyl)silyl]oxy-1-phenylethyl]-1-(hydroxymethyl)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one 3-Oxa-10-azatricyclo[4.3.1.0~2,4~]decane (3S,5R,6R,7R)-6-hydroxy-4,9-dioxa-1-azatricyclo[5.3.0.03,5]decan-10-one (1RS,2SR,4RS,5SR)-3-oxa-6-azatricyclo[3.2.1.02,4]octan-7-one (1S,6S)-1-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-[(1S)-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one 3-(methanesulfonyl)-7-oxa-3-azabicyclo[4.1.0]heptane 3α,4α-epoxy-2-piperidone (+)-tedanalactam 5-amino-1,2-anhydro-5-deoxy-D-lyxono-1,4-lactame (1R,5S,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,5R,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1S,6R)-4,4,6-trimethyl-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6S)-4,4,6-trimethyl-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6R)-3-(cyclopropylmethyl)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-ethyl-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-(2-methylpropyl)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-(2-methoxyethyl)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-methyl-7-oxa-3-azabicyclo[4.1.0]heptane (1S,6S)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6S)-7-oxa-2-azabicyclo[4.1.0]heptane (1S,6R)-7-oxa-2-azabicyclo[4.1.0]heptane (1R,6R)-7-oxa-3-azabicyclo[4.1.0]heptane (1S,2S,4R,5S)-4-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (2R,4S,7S)-3-oxa-1-azatricyclo[5.2.0.02,4]nonane (1S,2S,4S,5R)-4-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1S,2S,4S,5S)-4-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (2S,4R,7S)-3-oxa-1-azatricyclo[5.2.0.02,4]nonane (1R,6R)-1-methyl-3-propyl-7-oxa-3-azabicyclo[4.1.0]heptane (1S,2R,4S,5S)-2-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1R,2S,4S,5S)-2-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1S,2S,4S,5S)-2-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1R,6S)-3-methyl-7-oxa-3-azabicyclo[4.1.0]heptane